What is Endevica Bio?
Endevica Bio is a clinical-stage biopharmaceutical company focused on the development of novel peptidomimetics designed to address high-unmet-need conditions, specifically cancer cachexia and obesity. By engineering molecules that overcome the inherent limitations of traditional peptide therapeutics, such as poor stability and rapid degradation, the company aims to deliver safer and more effective treatment options. Its lead candidate, TCMCB07, is currently undergoing Phase 2 clinical evaluation for the treatment of cancer cachexia, while its secondary pipeline asset, 710GO, has demonstrated significant efficacy in preclinical weight loss models. The company's scientific approach centers on modulating specific biological pathways to improve patient quality of life without the adverse side effects often associated with existing pharmacological interventions.
How much funding has Endevica Bio raised?
Endevica Bio has raised a total of $10M across 1 funding round:
Series B
$10M
Series B (2023): $10M, investors not publicly disclosed
Key Investors in Endevica Bio
Undisclosed Investor
Undisclosed investor participating in the funding round.
What's next for Endevica Bio?
With this major strategic investment, Endevica Bio is well-positioned to advance its clinical pipeline through critical regulatory milestones. The primary focus for the upcoming fiscal periods will be the successful execution of the Phase 2 trial for TCMCB07, which serves as a key value-inflection point for the company. Furthermore, the firm is expected to allocate resources toward the preclinical optimization and potential IND-enabling studies for its obesity-focused assets. As the company scales its operations, it will likely prioritize strategic partnerships or licensing agreements to expand its reach in the global metabolic and oncology markets, ensuring that its innovative peptide therapeutics can reach a broader patient population while maintaining a lean, high-impact operational structure.
See full Endevica Bio company page
